CONMED Corp
CONMED Corp is a U.S.-based medical technology company focused on devices and equipment used in surgical procedures. Its portfolio spans orthopedic surgery and general surgery, with products used in sports medicine, lower-extremity procedures, minimally invasive laparoscopic and gastrointestinal surgery, electrosurgery, smoke evacuation, and cardiac monitoring. The company sells primarily to hospitals, surgery centers, surgeons, distributors, and large healthcare purchasing organizations, and it supports these customers through direct sales and distributor channels. CONMED manufactures substantially all of its products in the United States and Mexico and markets them globally, with a meaningful share of revenue coming from international markets. The business is characterized by a high mix of single-use products, which creates recurring demand tied to procedure volumes and installed capital equipment placements.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueSports medicine, lower-extremity, small bone, large bone and powered surgical products used in orthopedic procedures.
Minimally invasive laparoscopic and gastrointestinal devices, electrosurgery, smoke evacuation, insufflation and monitoring products.
Products
Reported · share of revenue- General Surgery58.2 %
- Orthopedic Surgery41.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
CONMED sells to a broad base of healthcare providers that use its devices in operating rooms and procedural suites. Its core customers include surgeons, hospitals, surgery centers, group purchasing organizations, integrated delivery networks, and medical specialty distributors. The company also serves large national and regional accounts, including Veterans Administration and other federal hospitals in the U.S. Customer demand is driven by procedure volumes, product performance, regulatory approval, and the ability to reduce supplier complexity and total cost of care. No single customer accounted for more than 10% of net sales in 2025, 2024, or 2023, which indicates a diversified customer base.
Buy orthopedic and general surgery devices for operating rooms, procedural suites and inpatient care, prioritizing reliability, breadth of portfolio and supply continuity.
Purchase recurring single-use surgical products and capital equipment for outpatient procedures, where efficiency and procedure-specific performance matter.
Influence purchasing decisions for large healthcare networks that want fewer suppliers, standardized products and better pricing.
Buy products for resale to healthcare providers, especially where customers prefer third-party inventory management and local distribution support.
Includes Veterans Administration and other federal hospitals that buy through institutional procurement channels.
Strategy
CONMED's strategy centers on portfolio optimization, manufacturing efficiency and geographic diversification. Management has said it continuously reviews the product portfolio, pursuing acquisitions and distribution arrangements where they add scale, technology or market access, while discontinuing products that no longer fit the strategy. The company is also focused on reducing operating costs and improving supply chain and manufacturing processes, reflecting pressure from inflation, tariffs and supply chain disruption. International expansion remains important because management sees growth opportunities outside the United States, especially in Europe, Latin America, Canada and Asia/Pacific. The planned exit from the Gore VIABIL biliary endoprosthesis distribution agreement and the remaining gastroenterology product line indicates a sharper focus on core surgical categories with better strategic fit and margin potential.
Management wants to focus resources on products that fit the core surgical strategy and improve margins.
Inflation, tariffs and supply chain challenges are pressuring costs, so operational improvements are needed to protect profitability.
Management sees meaningful growth opportunities outside the U.S. and wants to reduce dependence on any single market.
Geography
Q1/2026CONMED is headquartered in Largo, Florida and manufactures substantially all of its products in the United States and Mexico. The company markets products domestically and internationally, with international sales approximating 44% of consolidated net sales in 2025 and 43% in the first nine months of 2025. Management identifies Europe, Latin America, Canada and the Asia/Pacific Rim as principal international markets, which makes the business meaningfully exposed to foreign exchange, tariffs, import/export rules and local healthcare purchasing conditions. The company also sells through third-party distributors in some regions, including limited exposure to Ukraine and the Middle East, but those sales were described as not material. This geographic mix matters because manufacturing, distribution and tariff exposure are split across North America and multiple overseas end markets.
Share of the revenue the company reports by geography.
Risks
CONMED faces demand risk tied to healthcare spending, procedure volumes and broader economic conditions, since its products are used in elective and scheduled surgeries. The company is exposed to competitive and innovation risk because larger rivals may develop new technologies faster, and its products could become obsolete if it fails to keep pace. Regulatory, reimbursement and approval risk is important in medical devices because delays in approvals or lack of clinical evidence can slow adoption of new products. Operationally, inflation, tariffs, supply chain disruption and border taxes can raise costs and compress margins, while international sales expose the company to political, trade and foreign-government restrictions. The planned exit from the Gore VIABIL distribution agreement also creates transition risk as the company replaces revenue from a product line that generated meaningful sales in 2025.
- Product innovation and competitive pressureImpact: HighLikelihood: Medium
The company competes against larger medical device firms with greater R&D and commercialization resources, which can reduce demand for CONMED products.
Exposure: Orthopedic and general surgery franchises
- Tariffs and trade restrictionsImpact: HighLikelihood: Low
Manufacturing and sales span the U.S., Mexico and international markets, so tariffs and border taxes can directly affect cost structure and pricing.
Exposure: Cross-border supply chain and exports
- Dependence on healthcare procedure volumesImpact: High
Revenue is tied to surgical procedures, many of which can be delayed during economic weakness, staffing shortages or public health disruptions.
Exposure - Transition away from Gore VIABIL and gastroenterologyImpact: High
The company is ending a distribution agreement that contributed meaningful sales, so replacement revenue and margin mix must be managed carefully.
Exposure: Gastroenterology distribution
- Regulatory and approval delaysImpact: MediumLikelihood: Medium
Medical devices require approvals and clinical evidence, and delays can postpone launches or limit adoption of new products.
Exposure: New product pipeline
Accounting
Judgemental itemsAcquisition-driven growth makes impairment testing important if product performance or market conditions weaken.
Impact: Could create non-cash charges and affect equity and earnings
Acquisition earn-outs require fair value estimates that can change with performance assumptions.
Impact: Can introduce periodic remeasurement gains or losses
Actuarial assumptions such as discount rates and expected returns affect liabilities and expense.
Impact: Can move operating expense and balance sheet obligations
Single-use products, capital equipment and distribution arrangements have different margin and timing profiles.
Impact: Affects quarterly comparability and gross margin
Similar listed companies
Publicly listed companies with a comparable business focus.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
ResMed Inc
RMD · Surgical & Medical Instruments & Apparatus
iRadimed Corporation
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
InMode Ltd.
INMD · Electromedical & Electrotherapeutic Apparatus
INSMED Inc
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
ENvue Medical, Inc.
FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Last updated: 24/09/2026